Peroxisome proliferator-activated receptor-␥ (PPAR-␥) agonists not only improve metabolic abnormalities of diabetes and consequent diabetic nephropathy, but they also protect against nondiabetic chronic kidney disease in experimental models. Here, we found that the PPAR-␥ agonist pioglitazone protected against renal injury in aging; it reduced proteinuria, improved GFR, decreased sclerosis, and alleviated cell senescence. Increased local expression of PPAR-␥ paralleled these changes. Underlying mechanisms included increased expression of klotho, decreased systemic and renal oxidative stress, and decreased mitochondrial injury. Pioglitazone also regulated p66
Aging in most species is associated with impaired adaptive and homeostatic mechanisms, leading to susceptibility to environmental or internal stresses with increasing rates of disease and death. Kidney mass is substantially reduced in old age, by approximately 20 to 25% between the age of 30 and 80 yr 1 and a 0.5-cm decrease in length per decade after middle age. 2 The aging human kidney is characterized by increased glomerulosclerosis, interstitial fibrosis, tubular atrophy, and arteriosclerosis. 3, 4 A number of different theories of primarily diseaseindependent aging, which can be categorized as evolutionary, molecular, cellular, and systemic, have been put forward over the past 50 yr. From the cellular perspective, several mechanisms are considered to underlie the primary aging process and contribute to age-related changes and adaptive responses. These mechanisms include oxidative stress, mitochondrial dysfunction, telomere shortening, and various genetic modulations. 5 Pioglitazone, a peroxisome proliferator-activated receptor ␥ (PPAR␥) agonist and member of the thiazolidinedione (TZDs) class of antidiabetic drugs, improves insulin-mediated glucose uptake into skeletal muscle without increasing endogenous insulin secretion and improves dyslipidemia. PPAR␥ agonist was also effective in the treatment of non-insulin-dependent diabetes mellitus. 6 However, PPAR␥ also has nonmetabolic effects, such as regulating cell cycle, inhibiting inflammation, and modulating cytokine production. Our previous studies have shown that PPAR␥ agonist ameliorates nondiabetic glomerulosclerosis. 7, 8 Recently, a protective effect of pioglitazone against oxidative stress in liver and kidney of diabetic rabbits was reported. 9 Long-term exposure to pioglitazone improved mitochondrial function. Of note, mitochondria produce more than 90% of reactive oxygen species (ROS) after related injury. 10 More importantly, one study showed that the Pro/Ala PPAR␥ gene polymorphism, which is related to PPAR␥ activity and insulin sensitivity, is also associated with human longevity. 11 However, there is little information about PPAR modulation during aging. Because expression of PPAR␥ is reduced during aging and TZDs have many beneficial effects on aging-related molecules, 12 we hypothesized that pioglitazone could protect against aging-related renal injury. Our results indeed show that activation of PPAR␥ is protective against aging-related renal injury. Mechanisms of this effect are associated with increased klotho and reduced mitochondrial oxidation, which is signaled by increased p66
Shc phosphorylation through the protein kinase C-␤ pathway.
RESULTS

Pioglitazone Improves Glucose and Lipid Metabolism in Aging Rats
Pioglitazone decreased the mildly elevated serum glucose and improved triglycerides and cholesterol, especially LDL level (Table 1) in aging rats. There was no effect on insulin.
Pioglitazone Protects against Aging-Related Renal Injury and Increases Klotho
With aging, urinary protein excretion was dramatically increased at 24 mo in untreated aging control rats (Control; 648.50 Ϯ 79.52 versus baseline 51.59 Ϯ 12.80 mg/24 h; P Ͻ 0.05), and creatinine clearance (Ccr) at 24 mo was decreased to 0.38 Ϯ 0.09 ml/min (corresponding serum creatinine, approximately 4 mg/dl) compared with normal serum creatinine in our previous study in 18-mo-old rats (0.72 Ϯ 0.06 mg/dl). 13 Pioglitazone (Pio) significantly decreased proteinuria (227.56 Ϯ 71.63 mg/24 h, P Ͻ 0.05 versus Control) and improved Ccr (0.83 Ϯ 0.16 ml/min, P Ͻ 0.05 versus Control; Table 1 ).
At 24 mo, glomerulosclerosis, tubular atrophy, and interstitial fibrosis were present in all rats. Rats receiving the PPAR␥ agonist showed significant amelioration of the development of glomerulosclerosis compared with control (sclerosis index, 0 to 4 scale; Pio 1.41 Ϯ 0.36 versus Control 2.28 Ϯ 0.21; P Ͻ 0.05; Figure 1A ). Effects on tubulointerstitial fibrosis, assessed by point counting, paralleled glomerulosclerosis (Pio 5.21 Ϯ 1.26 versus Control 9.83 Ϯ 0.96%, P Ͻ 0.05; Figure 1A ).
In our previous study, plasminogen activator inhibitor-1 (PAI-1) and TGF␤ were decreased by the PPAR␥ agonist in the puromycin-induced focal segmental glomerulosclerosis model. 8 However, in this aging model, there was no significant difference in PAI-1 expression between the two groups (Pio 0.92 Ϯ 0.24 versus Control 1.61 Ϯ 0.22, P ϭ not significant), whereas P-Smad2, the major downstream signaling pathway of TGF␤, was significantly decreased (Pio 0.04 Ϯ 0.004 versus Control 0.42 Ϯ 0.15, P Ͻ 0.05; Figure 2 Figure 1B ).
Klotho, a novel antiaging molecule with manifold effects, including on ROS, was increased in the aging kidney by pioglitazone (Pio 0.41 Ϯ 0.05 versus Control 0.25 Ϯ 0.04, P Ͻ 0.05; Figure 3 ).
Pioglitazone Induces Renal PPAR␥ Expression
Normally, PPAR␥ is mainly expressed in the kidney in distal tubules, collecting ducts, and vascular smooth muscle cells. Pioglitazone stimulated PPAR␥ expression in proximal tubules, glomerular mesangial cells, podocytes, and parietal epithelial cells ( Figure 4A ). Renal PPAR␥ activity was significantly increased in the pioglitazone group compared with control (Pio 0.70 Ϯ 0.15 versus Control 0.22 Ϯ 0.02, P Ͻ 0.05; Figure  4B ).
Pioglitazone Reduces Both Systemic and Renal Oxidative Stress
The activation of PPAR␥ decreased urinary isoprostane excretion, a marker for systemic lipid oxidation (Pio 7.89 Ϯ 0.99 versus Control 24.03 Ϯ 4.53 ng/d, P Ͻ 0.05; Figure 5A ). Kidney immunostaining for 4-hydroxy-2-nonenal, another oxidative lipid marker, was also decreased in pioglitazone versus control (Pio 27.69 Ϯ 3.26 versus Control 44.50 Ϯ 6.56 positive cells/ HPF, P Ͻ 0.05; Figure 5B ). Renal superoxide dismutase pro- 
Pioglitazone Attenuates Mitochondrial Injury
More than 90% of ROS is produced by mitochondria. Previous studies have shown increased mitochondrial DNA deletion in aging kidneys. 14, 15 We found a trend to decrease mitochondrial DNA deletion in pioglitazone-treated rats (Pio 0.21 Ϯ 0.03 versus Control 0.58 Ϯ 0.19, P ϭ 0.096; Figure 6A ). However, pioglitazone significantly increased mitochondrial inner membrane integrity (Pio 24,299 Ϯ 3131 versus Control 17,542 Ϯ 3837 fluorescence units/mg protein, P Ͻ 0.05; Figure 6B ). Cytochrome C oxidase (also known as complex IV) is the terminal complex of the mitochondrial respiratory chain and is comprised of 13 different subunits encoded by 3 mitochondrial genes (subunits I, II, and III) and 10 nuclear genes (subunits IV-VIII). Cytochrome C oxidase IV remains relatively stable and therefore can be used as an internal control. Although there was no significant change in cytochrome C oxidase I/IV, pioglitazone did decrease total cytochrome C oxidase activity (Pio 2.81 Ϯ 0.18 versus Control 5.23 Ϯ 0.46 nmol/ min/mg protein, P Ͻ 0.05; Figure 7 ). 
Pioglitazone Decreases p66
Shc Phosphorylation through the Protein Kinase C-␤2 Pathway
As an anti-diabetic drug, pioglitazone is known to decrease protein kinase C-␤ expression. 16 In our model, pioglitazone decreased protein kinase C-␤2 in kidney (Pio 0.36 Ϯ 0.03 versus Control 0.71 Ϯ 0.14, P Ͻ 0.05; Figure 8A ) but did not change protein kinase C-␤1 expression.
Phosphorylated p66 Shc serves as an integration point for many signaling pathways that affect mitochondrial function and longevity. Once activated, p66
Shc oxidizes cytochrome C and induces opening of the mitochondrial permeability transition pore, generates more reactive oxygen species, and releases more pro-apoptotic factors into the cytosol. More importantly, p66
Shc can be regulated by the protein kinase C-␤ pathway. 17 In our study, pioglitazone did not significantly change the total expression level of p66
Shc but reduced the phosphorylation on its tyrosine site (Pio 0.48 Ϯ 0.05 versus Control 0.77 Ϯ 0.10 nmol/min/mg protein, P Ͻ 0.05; Figure  8B ).
DISCUSSION
Renal aging is associated with renal disease and nonrenal clinical complications in humans. 18 Using a suitable animal model, we report that pioglitazone protects renal injury in aging by reducing proteinuria, improving GFR, decreasing sclerosis, and alleviating cell senescence. We found decreased mitochondrial injury through reduced protein kinase C-␤ and p66
Shc phosphorylation. These results suggest novel effects of PPAR␥ agonist on mitochondrial injury that may be of particular relevance in aging-related renal injury. To our knowledge, this is the first study of long-term TZD treatment in aging. Interestingly, in this nondiabetic aging model, pioglitazone dramatically improved aging-related glomerulosclerosis, interstitial fibrosis, cell senescence, and renal function. Diminished PPAR␥ in adipose tissue and skeletal muscle and insulin resistance have been found in aging. 19 -21 Previous studies in the kidney showed that PPAR␥ activity was decreased in aging rats. 12 Our data showed that pioglitazone increased PPAR␥ expression and activity in the aging kidney, which paralleled decreased glomerulosclerosis and interstitial fibrosis. In addition, systemic oxidative stress and intima thickness in renal arteries were decreased in the treatment group (data not shown). Pioglitazone also improved the mildly elevated blood glucose and increased lipid in aging rats, which may also have contributed to its beneficial effects on renal injury. These data suggest that not only systemic but also local actions of pioglitazone are involved in protection of injury in the aging kidney.
In our study, pioglitazone reduced a key TGF␤ signaling pathway and oxidative stress and improved mitochondrial BASIC RESEARCH www.jasn.org function. Most of these actions are mediated through the PPAR␥ acting on PPAR␥ response elements in gene promoter segments. Pioglitazone suppression of TGF␤1-induced fibronectin mRNA expression is dependent on PPAR␥ activation. 22 A functional PPAR␥ response element has recently been identified in the rat catalase promoter of brain microvascular endothelial cells. 23 Klotho is a newly identified anti-aging factor with effects on insulin/IGF-1 signaling, ROS, and phosphate/calcium homeostasis. The klotho gene has two upstream noncanonical PPAR-␥ binding sites, and in normal young mice, PPAR␥ increases renal tubular klotho mRNA and protein expression in vitro and in vivo. 24 We found that pioglitazone treatment in aging also increased renal klotho expression by more than 60%, another possible contributor to its effects on senescence and ROS.
The free radical theory, one of the controversial theories of aging, proposes that free radical reactivity is inherent in biology and results in cumulative damage and senescence. Elevated levels of both oxidant-damaged DNA and protein are found in aged organisms. 25 We found increased urinary and renal lipid oxidation in aging rats, and pioglitazone attenuated those aging-related changes. Mitochondria are the major source of ROS in cells. 26 Because the mitochondrial chromosome codes for some electron carriers, mtDNA damage may indirectly inhibit respiration and stimulate ROS formation. In our study, pioglitazone had a trend to decrease mitochondrial DNA deletion and significantly increased mitochondrial inner membrane integrity. Previous data showed that PPAR␥ activation induced mitochondrial dysfunction and increased ROS production (oxidative ATP formation), resulting in a compensatory increase in glucose used and ATP formed by glycolysis. 27 However, those studies were done on liver, muscle, or astrocytes and observed the rapid and direct effects on mitochondria by PPAR␥. 28 The conflicting results may point to a tissue or time specificity with regard to the relative importance of different target sites.
Mechanisms of TZD's effect on mitochondria are complicated. 27 First, pioglitazone increases mtDNA. 10 Second, PPAR␥ and nuclear respiratory factor 1 transcription factors share a common coactivator, PPAR coactivator 1␣, 29 and nuclear respiratory factor 1 can promote mitochondrial biogenesis. Third, TZDs may affect coupling-uncoupling dynamics, which could in turn increase glucose utilization and influence free radical production/oxidative stress. 30, 31 Last, several findings suggest that activation of PPAR␥ may exert an antioxidant activity by favorably altering the expression of specific enzymes participating in the production and/or elimination of ROS in mitochondria, including e.g. NAD(P)H and catalase. 23, [32] [33] [34] We showed that pioglitazone also decreased total cytochrome C oxidase activity, although not its expression. More importantly, we found that phosphorylation of p66
Shc , a key modulator of mitochondrial function, was decreased in pioglitazone-treated rats. p66
Shc is a newly recognized gene associated with longevity in mice, and also serves as an integration point for many signaling pathways that affect mitochondrial function. 17 , 35 The extended life span of mice lacking p66
Shc has been correlated with a decrease in mitochondrial metabolism and reactive oxygen species production. 36, 37 Once activated, p66
Shc oxidizes cytochrome C and induces opening of the mitochondrial permeability transition pore, generates more ROS and releases more pro-apoptotic factors into the cytosol. Inhibiting or silencing protein kinase C-␤ protects cells against H 2 O 2 challenge. 38 Furthermore, over-expression of protein kinase C-␤ reproduces the mitochondrial fragmentation and Ca 2ϩ signaling defect in cells expressing p66 Shc , but not in cells lacking p66
Shc . Cells expressing a mutant form of p66 Shc (p66 Shc S36A) that cannot be phosphorylated also lack the early mitochondrial response to protein kinase C-␤ activity, indicating a requirement for p66
Shc phosphorylation. Interestingly, TZDs corrected the impaired protein kinase C pathway in our aging model, similar to observations in diabetic rats or high glucose-treated endothelial cells. 15, 39 This finding may be related to 5Ј-AMP-activated protein kinase (AMPK) or diacylglycerol kinase activation, two upstream inhibitors, which can be directly induced by TZDs. 16, 40 In our study, we did not assess PPAR␥-independent pathways that also may contribute to the beneficial effects of TZDs. Data suggest that TZDs modulate nitric oxide reduction, TNF-␣ production, and endothelial cell proliferation by PPAR␥-independent mechanisms. 41, 42 In vitro studies in renal tubular epithelium showed that lowering pioglitazone concentration activated both PPAR␥-driven gene expression and the PPAR␥-independent AMPK pathway, whereas a high dose of troglitazone activated the P-extracellular signal-regulated kinase pathway. 28 These findings indicate the effects of TZDs depend both on the specific agent and the dose, resulting in activation of different signaling pathways. Both PPAR␥ activation and decreased protein kinase C, which is downstream of AMPK, were found in our study in response to pioglitazone. Thus, we cannot exclude that a PPAR␥-independent pathway could also contribute to the observed effects.
In summary, our results support the hypothesis that increased oxidative stress associated with mitochondrial injury contributes to renal dysfunction, senescence, glomerulosclerosis, and proteinuria in the aging kidney. Our results further suggest that age-dependent renal injury can be protected by activation of PPAR␥ with associated increased klotho and reduced protein kinase C-␤ and p66
Shc phosphorylation.
CONCISE METHODS
Experimental Design and Animals
Aging male Sprague-Dawley rats from Zivic Miller Laboratories (Zellenople, PA) were studied. Aging rats were housed under controlled conditions with a 12-h light/dark cycle, at 70°F with 40% humidity and 12 air exchanges per hour. Rats received normal rat chow and water ad libitum ("5001" diet; rodent diet, 23.4% protein, 4.5% fat, 6.0% fiber, 0.40% sodium; Purina Laboratory, St. Louis, MO). At 18 mo of age, treatment with the PPAR␥ agonist pioglitazone added to chow (10 mg/kg per d, Pio, n ϭ 10) was begun, and rats were killed at the age of 24 mo and compared with age-matched untreated controls (Cont, n ϭ 7) housed under identical conditions.
Blood and Urinary Measurements
Animals were placed in metabolic cages for 24 h for urine collection at 18 and 24 mo. Urine protein was measured by Bio-Rad Protein Assay Kit (Bio-Rad Laboratories, Hercules, CA). Serum and urine creatinine was measured by Vitros CREA slides (Johnson & Johnson Clinical Diagnostics, Rochester, NY). Urinary excretion of isoprostane was measured by the EIA kit (Oxford Biomedical Research, Rochester Hills, MI).
Evaluation of Renal Tissue
Kidney tissue from rats at death was immersion fixed in 4% paraformaldehyde/phosphate-buffered saline (PBS) solution and routinely processed, and 4-m sections were stained with periodic acid-Schiff and Masson's trichrome. A semiquantitative score (sclerosis index Figure 8 . Pioglitazone modulates mitochondrial function through the protein kinase C-p66 ShC pathway in aging kidney. Pioglitazone reduced protein kinase C-␤2 expression in the kidney but did not change protein kinase C-␤1 expression (A). Pioglitazone reduced p66
ShC phosphorylation on its tyrosine site (B) (PKC, protein kinase C).
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[SI]) was used to evaluate the degree of glomerulosclerosis. The severity of sclerosis for each glomerulus was graded from 0 to 4ϩ as follows: 0 represents no lesion, and 1ϩ represents sclerosis of Ͻ25% of the glomerulus, whereas 2ϩ, 3ϩ, and 4ϩ represent sclerosis of 25 to 50, 50 to 75, and Ͼ75% of the glomerulus, respectively. A whole kidney average SI was obtained by averaging scores from all glomeruli on one section.
Cortical interstitial volume fraction (V/v interstitium/cortex) was assessed by point counting at ϫ200 on Masson trichrome-stained cortical sections. Tubulointerstitial fibrosis was also evaluated qualitatively on Masson's trichrome-stained section. All sections were examined without knowledge of the treatment protocol.
Immunohistochemistry
Four-micrometer sections were microwaved in 0.01 M sodium citrate (pH 6.0) three times for 5 min each. The primary antibodies used were rabbit anti-rat PPAR␥ (1:200; Cayman, Ann Arbor, MI), ED1 (1:50; Santa Cruz Biotechnology, Santa Cruz, CA), and rabbit anti-mouse 4-hydroxy-2-nonenal (1:800; Cell Signaling). Sections were incubated overnight at 4°C. Immunoperoxidase staining was performed with the Vectastain ABC kit (Vector Laboratories, Burlingame, CA), with diaminobenzidine as a chromogen. Hematoxylin was used as a counterstain.
Senescence-Associated ␤-Galactosidase Activity
Senescence-associated galactosidase activity was examined as described previously. 43 Briefly, frozen sections were washed and incubated at 37°C with freshly prepared senescence-associated ␤-galactosidase stain solution: 1 mg of 5-bromo-4-chloro-3-indolyl ␤-Dgalactoside/ml (stock solution, 20 mg/ml of dimethylformamide), 40 mM citric acid, sodium phosphate, pH 6.0, 5 mM potassium ferrocyanide, 5 mM potassium ferricyanide, 150 mM NaCl, and 2 mM MgCl 2 . Staining was evident in 16 h. The percentage of ␤-galactosidase-positive area was measured by point counting on 20 consecutive fields from kidneys from each rat evaluated at a magnification of ϫ100.
Western Blot
Frozen kidney tissue samples were transferred in radioimmunoprecipitation assay plus buffer containing 1:100 phosphatase inhibitor cocktail I, 1:100 phosphatase inhibitor cocktail II (Sigma, St. Louis, MO), 1:100 proteinase inhibitor cocktail tablet (Roche Diagnostics, Mannheim, Germany), samples were homogenized and centrifuged, and the protein concentration was measured using the Dc Protein Assay kit (Bio-Rad Laboratories, Hercules, CA). p66 Shc (1:2000; Abcam, Cambridge, MA), P-Tyr (1:400; Santa Cruz Biotechnology), cytochrome C oxidase I (1:400; Santa Cruz Biotechnology) and IV (1: 2500; Santa Cruz Biotechnology), protein kinase C-␤1 (1:400; Santa Cruz Biotechnology), protein kinase C-␤2 (1:1000; Sigma), PAI-1 (1:400; R&D Systems, Minneapolis, MN), NAPDH oxidase (NOX)4 (1:100; Abcam), NOX2 (1:250; Millipore), Cu/Zn SOD (1:1000; Millipore), klotho (1:500; R&D Systems), P-Smad2 (1:500; Cell Signaling, Boston, MA), and total-Smad2 (1:250; Zymed) were detected by using the corresponding antibody overnight at 4°C. Horseradish peroxidase-labeled donkey anti-rabbit or anti-mouse IgG secondary antibody (1:2500 in 5% milk TBS-T) was added and incubated at room temperature for 1 h. Protein bands on Western blots were visualized by ECL Plus (Amersham, Arlington Heights, IL) according to the manufacturer's instructions and were developed on film. ␤-actin was detected using mouse anti-␤-actin polyclonal antibody (Sigma). The ratio of specific message to ␤-actin or P-Smad2 to Total-Smad2 was used to quantify expression for each tissue sample.
PPAR␥ Activity
The activity of PPAR␥ was assessed by ELISA using a TransAM PPAR␥ Transcription Factor Assay Kit (Active Motif, Carlsbad, CA). This method is based on reaction of nuclear extracts (30 g protein) with specific oligonucleotide sequences coated on a microtiter plate. According to the manufacturer's instructions, the binding of activated PPAR␥ is shown by the addition of a primary polyclonal anti-PPAR␥ antibody, followed by a secondary antibody conjugated with horseradish peroxidase and the 3,3Ј,5,5Ј-tetramethylbenzidine substrate. Absorbance was read at 450 nm and, after the reaction was stopped with sulfuric acid, at 655 nm using a microtiter plate reader.
Mitochondrial Cytochrome C Activity
Isolation of rat renal mitochondria was performed with a mitochondrial isolation kit (Sigma). The mitochondrial inner membrane integrity was measured by the uptake of the fluorescence carbocyanine dye JC-1 into the mitochondria. The protein content of mitochondria and the mitochondrial supernatants was determined by the Biuret method with bovine serum albumin as standard. The mitochondrial-specific cytochrome C oxidase activity in the soluble and membrane-bound mitochondria sample was assayed for mitochondria activity using a commercial kit (Biochain Institute, Hayward, CA).
Mitochondrial DNA Deletion
Cortical tissue (100 mg) was homogenized, and mitochondrial DNA was extracted using an mtDNA extractor CT kit (Wako Pure Chemical Industries). The primers L4395 (5Ј-AGGACTTAACCAGAC-CCAAACACG-3Ј) and H5164 (5Ј-CCTCTTTTCTGATAGGCGGG-3Ј) were used to amplify a 770-bp DNA fragment, a highly conserved region that serves as a reference for total mtDNA, and primers L7825 (5Ј-TTTCTTCCCAAACCTTTCCT-3Ј) and H13117 (5Ј-AAGCCT-GCTAGGATGCTTC-3Ј) were used for the amplification of a 459-bp PCR product from 4834 bp-deleted mtDNA. The PCR reaction was performed in a 50-l reaction mixture containing 100 ng of total mtDNA, 0.2 mM of each dNTP, 1.0 l (5 units) of AmpliTaq Gold DNA polymerase (Applied Biosystems, Foster City, CA), 0.5 M of each primer, 15 mM Tris-HCl (pH 8.0), 50 mM KCl, 3 mM MgCl 2 , and 6 g/ml of albumin. After a hot start at 95°C for 12 min, amplification was performed for 30 cycles with 10 s of denaturation at 94°C, 30 s of annealing at 60°C, and 2 min of extension at 72°C, and a final extension was performed for 5 min at 72°C. The relative density of the 459-bp PCR product against the 770-bp product was calculated. 44 
Statistical Analysis
Results are expressed as mean Ϯ SEM. Statistical difference was assessed by a single-factor variance (ANOVA) followed by unpaired t test as appropriate. Nonparametric data were compared by MannWhitney U-test. P Ͻ 0.05 was considered significant.
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